We came across a bullish thesis on Novo Nordisk A/S on Kontra Investments’ Substack by Kontra. In this article, we will summarize the bull’s thesis on NVO. Novo Nordisk A/S’s share was trading at $70.73 as of June 24th. NVO’s trailing and forward P/E were 19.24 and 17.09, respectively, according to Yahoo Finance.
A picture of a pharma technician preparing an IV injection of a biopharmaceutical product.
Novo Nordisk continues to solidify its leadership in obesity treatment with...
